tradingkey.logo
tradingkey.logo
Search

Compugen Ltd

CGEN
Add to Watchlist
1.875USD
-0.065-3.35%
Close 10-26 16:00(ET)
177.62MMarket Cap
5.01P/E TTM

About Compugen Ltd Company

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Compugen Ltd Profile

Ticker SymbolCGEN
Company nameCompugen Ltd
IPO dateAug 01, 2000
CEOOphir (Eran)
Number of employees74
Security typeOrdinary Share
Fiscal year-endAug 01
AddressAzrieli Center
CityHOLON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code5885849
Phone97237658585
Websitehttps://cgen.com/
Ticker SymbolCGEN
IPO dateAug 01, 2000
CEOOphir (Eran)

Company Executives of Compugen Ltd

Name
Name/Position
Position
Shareholding
Change
Dr. Anat Cohen-Dayag, Ph.D.
Dr. Anat Cohen-Dayag, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
75.81K
+25.97%
Dr. Anat Cohen-Dayag, Ph.D.
Dr. Anat Cohen-Dayag, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
75.81K
+25.97%
Mr. David Silberman, CPA
Mr. David Silberman, CPA
Chief Financial Officer
Chief Financial Officer
55.00K
+35.45%
Mr. David Silberman, CPA
Mr. David Silberman, CPA
Chief Financial Officer
Chief Financial Officer
55.00K
+35.45%
Dr. Zurit Levine, Ph.D.
Dr. Zurit Levine, Ph.D.
Senior Vice President, Technology Innovation
Senior Vice President, Technology Innovation
47.38K
+37.99%
Dr. Zurit Levine, Ph.D.
Dr. Zurit Levine, Ph.D.
Senior Vice President, Technology Innovation
Senior Vice President, Technology Innovation
47.38K
+37.99%
Ms. Michelle Mahler
Ms. Michelle Mahler
Chief Medical Officer
Chief Medical Officer
36.63K
+36.86%
Ms. Michelle Mahler
Ms. Michelle Mahler
Chief Medical Officer
Chief Medical Officer
36.63K
+36.86%
Mr. Gilead Halevy
Mr. Gilead Halevy
Independent Director
Independent Director
18.91K
+39.67%
Mr. Gilead Halevy
Mr. Gilead Halevy
Independent Director
Independent Director
18.91K
+39.67%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Anat Cohen-Dayag, Ph.D.
Dr. Anat Cohen-Dayag, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
75.81K
+25.97%
Dr. Anat Cohen-Dayag, Ph.D.
Dr. Anat Cohen-Dayag, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
75.81K
+25.97%
Mr. David Silberman, CPA
Mr. David Silberman, CPA
Chief Financial Officer
Chief Financial Officer
55.00K
+35.45%
Mr. David Silberman, CPA
Mr. David Silberman, CPA
Chief Financial Officer
Chief Financial Officer
55.00K
+35.45%
Dr. Zurit Levine, Ph.D.
Dr. Zurit Levine, Ph.D.
Senior Vice President, Technology Innovation
Senior Vice President, Technology Innovation
47.38K
+37.99%
Dr. Zurit Levine, Ph.D.
Dr. Zurit Levine, Ph.D.
Senior Vice President, Technology Innovation
Senior Vice President, Technology Innovation
47.38K
+37.99%

FAQs

Who are the top five shareholders of Compugen Ltd?

The top five shareholders of Compugen Ltd are: Dr. Anat Cohen-Dayag, Ph.D.

How many institutions hold shares of Compugen Ltd (CGEN)?

As of 2026Q1, 124 institutions hold shares of Compugen Ltd, with a combined market value of approximately 13.75M, accounting for 14.54% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 445223.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.